Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

55 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations.
Banzhoff A, Haertel S, Praus M. Banzhoff A, et al. Hum Vaccin. 2011 May;7(5):539-48. doi: 10.4161/hv.7.5.14821. Epub 2011 May 1. Hum Vaccin. 2011. PMID: 21422814
INTRODUCTION: Systemic safety surveillance is an essential component of vaccination programmes to elucidate the full safety profile of a vaccine and to detect previously unrecognized adverse reactions that might be related to new vaccines. ...There were 36 deaths reported …
INTRODUCTION: Systemic safety surveillance is an essential component of vaccination programmes to elucidate the full safety profile of a
Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults.
Martinón-Torres F, Nolan T, Toneatto D, Banzhoff A. Martinón-Torres F, et al. Among authors: banzhoff a. Hum Vaccin Immunother. 2019;15(12):2940-2951. doi: 10.1080/21645515.2019.1627159. Epub 2019 Jul 9. Hum Vaccin Immunother. 2019. PMID: 31246520 Free PMC article. Review.
Comparison of the immunogenicity and safety of the purified chick embryo cell rabies vaccine manufactured in India and Germany: A randomized, single blind, multicentre, phase IV clinical study.
Sampath G, Banzhoff A, Deshpande A, Malerczyk C, Arora AK, Vakil H, Preiss S. Sampath G, et al. Among authors: banzhoff a. Hum Vaccin Immunother. 2017 Jul 3;13(7):1531-1538. doi: 10.1080/21645515.2017.1307483. Epub 2017 Apr 13. Hum Vaccin Immunother. 2017. PMID: 28406752 Free PMC article. Clinical Trial.
Combined administration of MF59-adjuvanted A/H5N1 prepandemic and seasonal influenza vaccines: long-term antibody persistence and robust booster responses 1 year after a one-dose priming schedule.
Lopez P, Caicedo Y, Sierra A, Tilman S, Clemens R, Banzhoff A. Lopez P, et al. Among authors: banzhoff a. Clin Vaccine Immunol. 2013 May;20(5):753-8. doi: 10.1128/CVI.00626-12. Epub 2013 Mar 27. Clin Vaccine Immunol. 2013. PMID: 23536690 Free PMC article. Clinical Trial.
Homologous and heterologous antibody responses to a one-year booster dose of an MF59(®) adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects.
Vesikari T, Forstén A, Borkowski A, Gaitatzis N, Banzhoff A, Clemens R. Vesikari T, et al. Among authors: banzhoff a. Hum Vaccin Immunother. 2012 Jul;8(7):921-8. doi: 10.4161/hv.20248. Epub 2012 Jul 1. Hum Vaccin Immunother. 2012. PMID: 22777094
Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.
Lopez P, Caicedo Y, Sierra A, Tilman S, Banzhoff A, Clemens R. Lopez P, et al. Among authors: banzhoff a. J Infect Dis. 2011 Jun 15;203(12):1719-28. doi: 10.1093/infdis/jir191. J Infect Dis. 2011. PMID: 21606530 Clinical Trial.
Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence.
Vesikari T, Karvonen A, Tilman S, Borkowski A, Montomoli E, Banzhoff A, Clemens R. Vesikari T, et al. Pediatrics. 2010 Oct;126(4):e762-70. doi: 10.1542/peds.2009-2628. Epub 2010 Sep 6. Pediatrics. 2010. PMID: 20819892 Clinical Trial.
OBJECTIVE: This study evaluated the immunogenicity, safety, and tolerability of a MF59-adjuvanted H5N1 vaccine in a population 6 months through 17 years of age. METHODS: Healthy subjects 6 to <36 months, 3 to <9 months, and 9 to <18 years of age were assign …
OBJECTIVE: This study evaluated the immunogenicity, safety, and tolerability of a MF59-adjuvanted H5N1 vaccine in a population …
Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.
Galli G, Hancock K, Hoschler K, DeVos J, Praus M, Bardelli M, Malzone C, Castellino F, Gentile C, McNally T, Del Giudice G, Banzhoff A, Brauer V, Montomoli E, Zambon M, Katz J, Nicholson K, Stephenson I. Galli G, et al. Proc Natl Acad Sci U S A. 2009 May 12;106(19):7962-7. doi: 10.1073/pnas.0903181106. Epub 2009 Apr 27. Proc Natl Acad Sci U S A. 2009. PMID: 19416838 Free PMC article. Clinical Trial.
The prevaccination frequency of circulating memory B cells reactive to A/Vietnam/1194/2004 was low in both primed and unprimed individuals. ...We conclude that distant priming with clade 0-like H5N3 induces a pool of cross-reactive memory B cells that can be boosted …
The prevaccination frequency of circulating memory B cells reactive to A/Vietnam/1194/2004 was low in both primed and unprimed indivi …
Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1.
Stephenson I, Nicholson KG, Hoschler K, Zambon MC, Hancock K, DeVos J, Katz JM, Praus M, Banzhoff A. Stephenson I, et al. N Engl J Med. 2008 Oct 9;359(15):1631-3. doi: 10.1056/NEJMc0805274. N Engl J Med. 2008. PMID: 18843132 No abstract available.
MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults.
Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, Capecchi PL, di Giovanni P, Sticchi L, Gentile C, Hilbert A, Brauer V, Tilman S, Podda A. Banzhoff A, et al. PLoS One. 2009;4(2):e4384. doi: 10.1371/journal.pone.0004384. Epub 2009 Feb 6. PLoS One. 2009. PMID: 19197383 Free PMC article. Clinical Trial.
METHODS AND FINDINGS: Healthy adults aged 18-60 and > 60 years (n = 313 and n = 173, respectively) were randomized (1:1) to receive two primary and one booster injection of 7.5 microg or 15 microg doses of a subunit MF59-adjuvanted H5N1 (A/Vietnam/1194/2004) (cla …
METHODS AND FINDINGS: Healthy adults aged 18-60 and > 60 years (n = 313 and n = 173, respectively) were randomized (1:1) to receive two p …
55 results
Jump to page
Feedback